GET DAILY SIGNALSargenx (ARGX) Posts Strong Q3 2026 Revenue as Vyvgart Sales Surge 54%
Key Takeaways
- argenx reported third quarter 2026 total revenue of $1.75 billion, up from $1.15 billion in the prior-year period.
- Product net sales of Vyvgart reached $1.72 billion, rising 54% year over year and 13% quarter over quarter.
- Net income climbed to $506 million, with diluted earnings per share (EPS) of $7.80 versus $5.18 a year earlier.
- Vyvgart sales beat consensus, but operating profit of $486 million came in below analyst expectations.
- The company now expects combined research and development (R&D) and selling, general and administrative (SG&A) expenses of roughly $4 billion for full-year 2026.
Earnings Context and Why It Matters
argenx SE, a Belgium-based immunology company, has built its growth story around Vyvgart (efgartigimod), a treatment for autoimmune conditions including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This quarterly report carries added weight because it reflects the company's first results since closing its acquisition of Forte Biosciences, a move that expanded its pipeline and reshaped its near-term expense profile. For investors, the print offers a key read on whether Vyvgart's commercial momentum can keep funding a growing research pipeline while the company absorbs acquisition-related costs. The results also test management's guidance on operating leverage heading into 2027.
Reported Results
Total revenue for the three months ended September 30, 2026 was $1.751 billion, up from $1.151 billion in the same period of 2025. Product net sales of Vyvgart reached $1.72 billion, a 54% year-over-year increase, driven by continued patient growth across gMG and CIDP. Net income rose to $506 million from $344 million a year earlier, with basic EPS of $8.07 compared to $5.61 and diluted EPS of $7.80 compared to $5.18.
On a nine-month basis, revenue reached $4.605 billion versus $2.926 billion in the prior year, while net income climbed to $1.344 billion from $759 million. The company reported operating profit of $486 million, reflecting a 28% operating margin, or 37% when adjusted for one-time Forte transaction costs. Combined R&D and SG&A expenses totaled $1.1 billion for the quarter, up 22% sequentially, including about $150 million of acquisition-related costs. The company ended the quarter with $3.7 billion in cash, cash equivalents, and current financial assets after paying roughly $2.1 billion, net of acquired cash, for Forte Biosciences. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Investor response to the print was mixed. Vyvgart sales of $1.72 billion came in about 6% above consensus estimates, and total revenue of $1.75 billion also exceeded expectations, underscoring the strength of the franchise. However, operating profit of $486 million landed roughly 11% below the Visible Alpha consensus, reflecting higher-than-anticipated spending tied to the Forte acquisition and broader pipeline investments. Shares showed choppy trading around the release, initially easing as the operating profit miss offset the revenue beat. Management's commentary on continued margin expansion in 2027 and its confidence in underappreciated top-line growth helped frame the results for analysts, though the near-term expense guidance remained a key focus of the reaction. From what I see, the revenue beat highlights the franchise strength while the expense side warrants closer monitoring.
Forward Outlook and Key Factors to Monitor
argenx has raised its full-year 2026 expense outlook, now expecting combined R&D and SG&A spending of approximately $4 billion, including Forte transaction costs and investment into FB-102, the celiac disease candidate acquired through the Forte deal. Management has signaled that it expects to keep expanding operating margin into 2027, with more detailed guidance anticipated early next year.
Investors should watch several catalysts closely. The company is advancing supplemental regulatory filings for Vyvgart in ocular and pediatric myasthenia gravis, with a pediatric review decision date set for February 2027. It is also preparing to move FB-102 into a Phase 3 trial in celiac disease and is pursuing immune-mediated necrotizing myopathy (IMNM) as a potential next indication for the Vyvgart franchise.
At the same time, argenx recently discontinued a trial in Sjögren's disease, with full data analysis still pending. The balance between rising investment and the pace of revenue growth will remain central to the story, as will the company's ability to sustain patient growth in gMG and CIDP while expanding into new markets. The next full update is scheduled for February 25, 2027, when the company reports full-year 2026 results. I’m watching this closely as the company balances growth with the integration costs from the recent acquisition.
Using Tickeron’s AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Screener help cut through the noise when evaluating how a company like argenx stacks up against peers on fundamentals and technical signals. I also checked this using Tickeron’s AI Trend Prediction Engine to see how the stock compares to others in the industry. These resources allow me to quickly surface comparable names and confirm patterns that align with the quarterly data, supporting a more informed view of the investment case without replacing traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARGX's RSI Oscillator ascends from oversold territory
The RSI Oscillator for ARGX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 16 of the 20 cases the stock moved higher. This puts the odds of a move higher at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 55 cases where ARGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for ARGX just turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
Following a +7.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 217 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
ARGX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for ARGX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.615) is normal, around the industry mean (2.988). P/E Ratio (32.074) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of antibody-based medicines
Industry Biotechnology
Advertisement